FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
The FDA’s approval of resmetirom (Rezdiffra) marks a significant breakthrough in treating metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, conditions linked to non-alcoholic fatty liver disease (NAFLD). MASH is a growing global health concern, and resmetirom offers a novel thera...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2024-12-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A100878/100878.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825199561504718848 |
|---|---|
| author | Muhammad Mazhar Azam Sameen Mukhtar Muhammad Haris Fatima Laique Suhaina Amir Mubashir Mohiuddin Bibek Giri |
| author_facet | Muhammad Mazhar Azam Sameen Mukhtar Muhammad Haris Fatima Laique Suhaina Amir Mubashir Mohiuddin Bibek Giri |
| author_sort | Muhammad Mazhar Azam |
| collection | DOAJ |
| description | The FDA’s approval of resmetirom (Rezdiffra) marks a significant breakthrough in treating metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, conditions linked to non-alcoholic fatty liver disease (NAFLD). MASH is a growing global health concern, and resmetirom offers a novel therapeutic option by targeting liver pathophysiology through thyroid hormone receptor-beta activation. This mechanism effectively reduces fibrosis markers, improves liver enzyme levels, and minimizes liver fat buildup. Clinical trials have shown that resmetirom has a favorable safety profile, with manageable side effects like diarrhea and nausea. Additionally, it may lower cardiovascular risks associated with MASH, enhancing patient outcomes and quality of life. As the first FDA-approved drug for MASH, resmetirom’s introduction fills a crucial treatment gap, providing new hope for millions of patients and representing a pivotal moment in hepatology. |
| format | Article |
| id | doaj-art-3bd88345b481461abc0332078bb3179c |
| institution | Kabale University |
| issn | 2836-7677 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Open Exploration |
| record_format | Article |
| series | Exploration of Drug Science |
| spelling | doaj-art-3bd88345b481461abc0332078bb3179c2025-02-08T03:28:18ZengOpen ExplorationExploration of Drug Science2836-76772024-12-01286787410.37349/eds.2024.00078FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH managementMuhammad Mazhar Azam0Sameen Mukhtar1Muhammad Haris2Fatima Laique3Suhaina Amir4Mubashir Mohiuddin5Bibek Giri6https://orcid.org/0009-0003-0100-9111Department of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanDepartment of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanDepartment of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanDepartment of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanDepartment of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanDepartment of Medicine, Dow University of Health Sciences, Karachi 74000, PakistanResearch Institute for Collaborative Development, Kathmandu 44600, NepalThe FDA’s approval of resmetirom (Rezdiffra) marks a significant breakthrough in treating metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, conditions linked to non-alcoholic fatty liver disease (NAFLD). MASH is a growing global health concern, and resmetirom offers a novel therapeutic option by targeting liver pathophysiology through thyroid hormone receptor-beta activation. This mechanism effectively reduces fibrosis markers, improves liver enzyme levels, and minimizes liver fat buildup. Clinical trials have shown that resmetirom has a favorable safety profile, with manageable side effects like diarrhea and nausea. Additionally, it may lower cardiovascular risks associated with MASH, enhancing patient outcomes and quality of life. As the first FDA-approved drug for MASH, resmetirom’s introduction fills a crucial treatment gap, providing new hope for millions of patients and representing a pivotal moment in hepatology.https://www.explorationpub.com/uploads/Article/A100878/100878.pdfmetabolic dysfunction-associated steatohepatitis (mash)non-alcoholic fatty liver disease (nafld)resmetiromliverfibrosisthyroid |
| spellingShingle | Muhammad Mazhar Azam Sameen Mukhtar Muhammad Haris Fatima Laique Suhaina Amir Mubashir Mohiuddin Bibek Giri FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management Exploration of Drug Science metabolic dysfunction-associated steatohepatitis (mash) non-alcoholic fatty liver disease (nafld) resmetirom liver fibrosis thyroid |
| title | FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management |
| title_full | FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management |
| title_fullStr | FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management |
| title_full_unstemmed | FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management |
| title_short | FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management |
| title_sort | fda s approval of resmetirom rezdiffra a breakthrough in mash management |
| topic | metabolic dysfunction-associated steatohepatitis (mash) non-alcoholic fatty liver disease (nafld) resmetirom liver fibrosis thyroid |
| url | https://www.explorationpub.com/uploads/Article/A100878/100878.pdf |
| work_keys_str_mv | AT muhammadmazharazam fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT sameenmukhtar fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT muhammadharis fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT fatimalaique fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT suhainaamir fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT mubashirmohiuddin fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement AT bibekgiri fdasapprovalofresmetiromrezdiffraabreakthroughinmashmanagement |